-71%

est. 2Y upside i

HealthcareSeries A

Meet Freed: The AI assistant loved by 20,000+ happy clinicians. Freed listens, transcribes, and creates comprehensive SOAP notes faster than you can say "documentation backlog."

Rank

#1679

Sector

Healthcare AI / Digital Health

Est. Liquidity

~5Y

Data Quality

Data: Medium

Freed is a high-growth ($19M ARR, +134% YoY) AI health tech company with strong investor backing.

Last updated: March 10, 2026

Bull (17%)+250%

Freed successfully expands its AI clinician assistant platform beyond core scribing into comprehensive workflow and revenue cycle management, fending off incumbents with superior user experience and specialized AI models. This drives ARR to over $100M by 2028, justifying a $665M+ valuation at a 6.6x ARR multiple, well above the current $190M.

Base (46%)+100%

Freed maintains its strong growth in the small practice segment but faces increasing pressure from incumbent solutions and commoditization in the core AI scribe market. It reaches ~$50M ARR by 2028, leading to an acquisition or IPO at a $380M valuation, a 2x return on current valuation.

Bear (37%)-80%

Large incumbents like Microsoft (Nuance) and EHR providers (Epic with Abridge) integrate 'good enough' AI scribe features, commoditizing the market and eroding Freed's pricing power. Growth stalls, leading to a down round or acquisition at a significantly reduced valuation of $38M, wiping out most common stock value given $34M in liquidation preferences.

Est. time to liquidity~5.0 years

Preference Stack Risk

high

Investors hold $34M in liquidation preferences, representing 17.9% of the estimated current $190M valuation.

Dilution Risk

high

As a Series A company, Freed will likely raise additional funding rounds (Series B, C, etc.), which will dilute existing equity holders.

Secondary Liquidity

none

No active secondary market or tender offers are typically available for a Series A company.

Engineering — 6 roles

Marketing — 3 roles

Customer Success — 1 role

View all 10 open roles at Freed →

Last updated: March 10, 2026

Questions to Ask at the Interview

Strategic questions based on Freed's data — designed to show you've done your homework.

  • 1

    “Given the high incumbent threat from companies like Microsoft's Nuance and Epic's Abridge integration, how does Freed plan to maintain its competitive edge and pricing power over the next 2-3 years?”

  • 2

    “Freed is expanding into AI-Powered Clinical Workflow & Revenue Cycle Management. What specific product features or partnerships are critical to successfully capturing market share in this segment, and how will this impact the current ARR growth trajectory?”

  • 3

    “As a Series A company with $34M in total funding, how does Freed envision the path to a liquidity event for employees, and what are the key milestones the company aims to achieve to de-risk future funding rounds and ensure a favorable outcome for common shareholders?”

Community

Valuation Sentiment

Our model estimates -71% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.